SCYNEXIS Balance Sheet Health
Financial Health criteria checks 5/6
SCYNEXIS has a total shareholder equity of $58.5M and total debt of $13.2M, which brings its debt-to-equity ratio to 22.6%. Its total assets and total liabilities are $99.0M and $40.5M respectively.
Key information
22.6%
Debt to equity ratio
US$13.23m
Debt
| Interest coverage ratio | n/a |
| Cash | US$68.83m |
| Equity | US$58.53m |
| Total liabilities | US$40.51m |
| Total assets | US$99.04m |
Recent financial health updates
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 08
SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Apr 04Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Recent updates
Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 08Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop
Jun 19SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 12SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly
Apr 04Scynexis: Update Following Restructuring Of GSK Deal
Apr 02Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S
Feb 01Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Dec 21Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding
Sep 26Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?
Aug 17Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating
Aug 26SCYNEXIS Q2 2022 Earnings Preview
Aug 12FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment
Aug 01SCYNEXIS gains after favorable data for antifungal agent in new indication
Jul 19SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially
Apr 07SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying
Mar 07Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates
Feb 13Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?
Dec 03Scynexis: Leading The Yeast Infection Treatment Industry
Jul 27Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections
Jun 09FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment
Jun 02Financial Position Analysis
Short Term Liabilities: SCYX's short term assets ($80.5M) exceed its short term liabilities ($25.7M).
Long Term Liabilities: SCYX's short term assets ($80.5M) exceed its long term liabilities ($14.8M).
Debt to Equity History and Analysis
Debt Level: SCYX has more cash than its total debt.
Reducing Debt: SCYX's debt to equity ratio has reduced from 130.8% to 22.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SCYX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SCYX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.